400 related articles for article (PubMed ID: 28680167)
1. Efficiency and specificity of RAAS inhibitors in cardiovascular diseases: how to achieve better end-organ protection?
Nehme A; Zibara K
Hypertens Res; 2017 Nov; 40(11):903-909. PubMed ID: 28680167
[TBL] [Abstract][Full Text] [Related]
2. Optimal antagonism of the Renin-Angiotensin-aldosterone system: do we need dual or triple therapy?
Werner C; Pöss J; Böhm M
Drugs; 2010 Jul; 70(10):1215-30. PubMed ID: 20568830
[TBL] [Abstract][Full Text] [Related]
3. Blocking the RAAS at different levels: an update on the use of the direct renin inhibitors alone and in combination.
Cagnoni F; Njwe CA; Zaninelli A; Ricci AR; Daffra D; D'Ospina A; Preti P; Destro M
Vasc Health Risk Manag; 2010 Aug; 6():549-59. PubMed ID: 20730071
[TBL] [Abstract][Full Text] [Related]
4. Renin-angiotensin-aldosterone system inhibition: overview of the therapeutic use of angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, mineralocorticoid receptor antagonists, and direct renin inhibitors.
Mercier K; Smith H; Biederman J
Prim Care; 2014 Dec; 41(4):765-78. PubMed ID: 25439533
[TBL] [Abstract][Full Text] [Related]
5. Cardiorenal protection during chronic renin-angiotensin-aldosterone system suppression: evidences and caveats.
Ruiz-Hurtado G; Ruilope LM
Eur Heart J Cardiovasc Pharmacother; 2015 Apr; 1(2):126-31. PubMed ID: 27533982
[TBL] [Abstract][Full Text] [Related]
6. Current status of renin-aldosterone angiotensin system-targeting anti-hypertensive drugs as therapeutic options for Alzheimer's disease.
Ashby EL; Kehoe PG
Expert Opin Investig Drugs; 2013 Oct; 22(10):1229-42. PubMed ID: 23800077
[TBL] [Abstract][Full Text] [Related]
7. It is time to reconsider the cardiovascular protection afforded by RAAS blockade -- overview of RAAS systems.
Tsukamoto O; Kitakaze M
Cardiovasc Drugs Ther; 2013 Apr; 27(2):133-8. PubMed ID: 22147138
[TBL] [Abstract][Full Text] [Related]
8. Dual blockade of the renin-angiotensin-aldosterone system: beyond the ACE inhibitor and angiotensin-II receptor blocker combination.
Bomback AS; Toto R
Am J Hypertens; 2009 Oct; 22(10):1032-40. PubMed ID: 19661925
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of the renin-angiotensin-aldosterone system for cerebrorenal protection.
Lambers Heerspink HJ
Contrib Nephrol; 2013; 179():7-14. PubMed ID: 23652444
[TBL] [Abstract][Full Text] [Related]
10. The evolving landscape of RAAS inhibition: from ACE inhibitors to ARBs, to DRIs and beyond.
Epstein BJ; Leonard PT; Shah NK
Expert Rev Cardiovasc Ther; 2012 Jun; 10(6):713-25. PubMed ID: 22894628
[TBL] [Abstract][Full Text] [Related]
11. Hypertension: renin-angiotensin-aldosterone system alterations.
Te Riet L; van Esch JH; Roks AJ; van den Meiracker AH; Danser AH
Circ Res; 2015 Mar; 116(6):960-75. PubMed ID: 25767283
[TBL] [Abstract][Full Text] [Related]
12. Renal and cardio-protective effects of direct renin inhibition: a systematic literature review.
Lambers Heerspink HJ; Perkovic V; de Zeeuw D
J Hypertens; 2009 Dec; 27(12):2321-31. PubMed ID: 19727007
[TBL] [Abstract][Full Text] [Related]
13. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of the renin angiotensin aldosterone system: focus on aliskiren.
Rao MS
J Assoc Physicians India; 2010 Feb; 58():102-8. PubMed ID: 20653151
[TBL] [Abstract][Full Text] [Related]
15. Beneficial long-term effect of aldosterone antagonist added to a traditional blockade of the renin-angiotensin-aldosterone system among patients with obesity and proteinuria.
Morales E; Gutiérrez E; Caro J; Sevillano A; Rojas-Rivera J; Praga M
Nefrologia; 2015; 35(6):554-61. PubMed ID: 26519114
[TBL] [Abstract][Full Text] [Related]
16. Renin Angiotensin Aldosterone System Inhibitors in Hypertension: Is There Evidence for Benefit Independent of Blood Pressure Reduction?
Bavishi C; Bangalore S; Messerli FH
Prog Cardiovasc Dis; 2016; 59(3):253-261. PubMed ID: 27777044
[TBL] [Abstract][Full Text] [Related]
17. Renin-angiotensin-aldosterone system inhibitors in heart failure.
Shearer F; Lang CC; Struthers AD
Clin Pharmacol Ther; 2013 Oct; 94(4):459-67. PubMed ID: 23852393
[TBL] [Abstract][Full Text] [Related]
18. Sex differences in heart failure medications targeting the renin-angiotensin-aldosterone system.
Nicolaou PA
Eur J Pharmacol; 2021 Apr; 897():173961. PubMed ID: 33617824
[TBL] [Abstract][Full Text] [Related]
19. [Role of RAAS inhibitors for the treatment of heart failure].
Murohara T
Nihon Rinsho; 2012 Sep; 70(9):1577-81. PubMed ID: 23012806
[TBL] [Abstract][Full Text] [Related]
20. Addressing the theoretical and clinical advantages of combination therapy with inhibitors of the renin-angiotensin-aldosterone system: antihypertensive effects and benefits beyond BP control.
Ferrario CM
Life Sci; 2010 Feb; 86(9-10):289-99. PubMed ID: 19958778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]